240 related articles for article (PubMed ID: 18504306)
1. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.
Uria MJ; Zhang Q; Li Y; Chan A; Exley RM; Gollan B; Chan H; Feavers I; Yarwood A; Abad R; Borrow R; Fleck RA; Mulloy B; Vazquez JA; Tang CM
J Exp Med; 2008 Jun; 205(6):1423-34. PubMed ID: 18504306
[TBL] [Abstract][Full Text] [Related]
2. The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease.
Kugelberg E; Gollan B; Farrance C; Bratcher H; Lucidarme J; Ibarz-Pavón AB; Maiden MC; Borrow R; Tang CM
PLoS One; 2010 Feb; 5(2):e9413. PubMed ID: 20195528
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
Lucidarme J; Louth J; Townsend-Payne K; Borrow R
Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
[TBL] [Abstract][Full Text] [Related]
4. Serogroup B meningococcal vaccines-an unfinished story.
Sadarangani M; Pollard AJ
Lancet Infect Dis; 2010 Feb; 10(2):112-24. PubMed ID: 20113980
[TBL] [Abstract][Full Text] [Related]
5. Serum bactericidal antibody assays - The role of complement in infection and immunity.
McIntosh ED; Bröker M; Wassil J; Welsch JA; Borrow R
Vaccine; 2015 Aug; 33(36):4414-21. PubMed ID: 26187262
[TBL] [Abstract][Full Text] [Related]
6. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune responses to Neisseria meningitidis in children.
Pollard AJ; Galassini R; van der Voort EM; Booy R; Langford P; Nadel S; Ison C; Kroll JS; Poolman J; Levin M
Infect Immun; 1999 May; 67(5):2441-51. PubMed ID: 10225907
[TBL] [Abstract][Full Text] [Related]
9. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.
van den Broek B; van Els CACM; Kuipers B; van Aerde K; Henriet SS; de Groot R; de Jonge MI; Langereis JD; van der Flier M
Clin Exp Immunol; 2019 Dec; 198(3):381-389. PubMed ID: 31487400
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
Frasch CE; Borrow R; Donnelly J
Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
[TBL] [Abstract][Full Text] [Related]
11. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
12. [Human resistance to generalized bacterial infections (exemplified by meningococcal infection)].
Platonov AE
Vestn Ross Akad Med Nauk; 1999; (5):40-5. PubMed ID: 10394300
[TBL] [Abstract][Full Text] [Related]
13. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
[TBL] [Abstract][Full Text] [Related]
14. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.
Li Y; Zhang Q; Winterbotham M; Mowe E; Gorringe A; Tang CM
Infect Immun; 2006 Nov; 74(11):6348-55. PubMed ID: 16966413
[TBL] [Abstract][Full Text] [Related]
15. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.
Jodar L; Cartwright K; Feavers IM
Biologicals; 2000 Sep; 28(3):193-7. PubMed ID: 10964447
[No Abstract] [Full Text] [Related]
16. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
[TBL] [Abstract][Full Text] [Related]
18. The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.
Kahler CM; Martin LE; Shih GC; Rahman MM; Carlson RW; Stephens DS
Infect Immun; 1998 Dec; 66(12):5939-47. PubMed ID: 9826376
[TBL] [Abstract][Full Text] [Related]
19. Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.
Schmiel DH; Moran EE; Keiser PB; Brandt BL; Zollinger WD
Infect Immun; 2011 Oct; 79(10):4146-56. PubMed ID: 21768280
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.
Li Y; Sun YH; Ison C; Levine MM; Tang CM
Infect Immun; 2004 Jan; 72(1):345-51. PubMed ID: 14688114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
